Center-Authored Papers

Filters: Author is Chauncey, Thomas R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA et al..  2008.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(30):4912-20. Abstract
Scott BL, Park JY, Deeg HJ, Marr KA, Boeckh MJ, Chauncey TR, Appelbaum FR, Storb R, Storer BE.  2008.  Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(7):799-806. Abstract
Sorror ML, Storer BE, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, Maziarz RT, Pulsipher M, McSweeney PA, Storb R.  2008.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.. Cancer. 112(9):1992-2001. Abstract
Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM et al..  2008.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):246-55. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Rezvani AR, Storer BE, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey TR, Forman SJ, Lange T et al..  2008.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2):211-7. Abstract
2009
Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P et al..  2009.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.. Blood. 113(14):3383-91. Abstract
Baron F, Petersdorf EW, Gooley TA, Sandmaier BM, Malkki M, Chauncey TR, Maloney DG, Storb R.  2009.  What is the role for donor natural killer cells after nonmyeloablative conditioning? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(5):580-8. Abstract
Furlong T, Martin PJ, Flowers MED, Carnevale-Schianca F, Yatscoff R, Chauncey TR, Appelbaum FR, Deeg HJ, Doney K, Witherspoon RP et al..  2009.  Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.. Bone marrow transplantation. 44(11):739-48. Abstract
2010
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher MA, Petersen FB, Wade JC, Maris MB, Bruno B et al..  2010.  Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(3):384-94. Abstract
Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT et al..  2010.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2859-67. Abstract
2011
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey AE, Flowers MED, Maris MB, Laport GG, Chauncey TR, Lange T et al..  2011.  Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.. Haematologica. 96(8):1113-20. Abstract
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P et al..  2011.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.. JAMA : the journal of the American Medical Association. 306(17):1874-83. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
2012
Khera N, Jinneman J, Storer BE, Heimfeld S, O'Meara MM, Chauncey TR, Lee SJ, Linenberger ML.  2012.  Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):220-228. Abstract
Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, Inamoto Y, Chauncey TR, Storb R, Appelbaum FR et al..  2012.  Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.. Blood. 119(11):2675-2678. Abstract
Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R et al..  2012.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.. Blood. 119(11):2657-2664. Abstract
Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer BE, Zaia JA, Forman S, Negrin RS, Chauncey TR, Bensinger WI et al..  2012.  Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1):66-75. Abstract
2013
Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B et al..  2013.  Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1340-7. Abstract
Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F et al..  2013.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(12):1530-8. Abstract
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract
2014
Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR et al..  2014.  A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after nonmyeloablative unrelated donor transplantation.. Haematologica. 99(10):1624-31. Abstract
Acute Disease
Mielcarek M, Burroughs L, Leisenring W, Diaconescu R, Martin PJ, Sandmaier BM, Maloney DG, Maris MB, Chauncey TR, Shizuru JA et al..  2005.  Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.. British journal of haematology. 129(3):381-91. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract